DarioHealth (DRIO) and Its Rivals Critical Contrast

DarioHealth (NASDAQ:DRIO) is one of 93 public companies in the “Healthcare Technology” industry, but how does it compare to its competitors? We will compare DarioHealth to related businesses based on the strength of its earnings, profitability, institutional ownership, risk, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for DarioHealth and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1	1	3	0	2.40
DarioHealth Competitors	448	1520	2729	88	2.51

DarioHealth presently has a consensus target price of $9.00, suggesting a potential upside of 199.80%. As a group, “Healthcare Technology” companies have a potential upside of 37.97%. Given DarioHealth’s higher probable upside, research analysts plainly believe DarioHealth is more favorable than its competitors.

Volatility and Risk

DarioHealth has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, DarioHealth’s competitors have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.

Institutional & Insider Ownership

33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 42.3% of shares of all “Healthcare Technology” companies are owned by institutional investors. 3.5% of DarioHealth shares are owned by company insiders. Comparatively, 16.0% of shares of all “Healthcare Technology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares DarioHealth and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DarioHealth	-169.87%	-54.81%	-33.36%
DarioHealth Competitors	-778.93%	-33.97%	-15.65%

Earnings and Valuation

This table compares DarioHealth and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
DarioHealth	$22.36 million	-$41.71 million	-0.49
DarioHealth Competitors	$341.86 million	-$24.15 million	13.10

DarioHealth’s competitors have higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

DarioHealth competitors beat DarioHealth on 9 of the 13 factors compared.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.